Colorectal Neoplasms Clinical Trial
Official title:
A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer
Background:
- Irinotecan is a drug that is used to treat colon or rectal cancer. It affects the DNA of
growing cancer cells. It is most often used with other chemotherapy drugs. Researchers want
to test it with an experimental drug, ISIS 183750. They want to see if the drugs are a safe
and effective treatment for advanced solid tumors or colorectal cancer that has not
responded to other treatments.
Objectives:
- To test the safety and effectiveness of ISIS 183750 with irinotecan for advanced solid
tumors or colorectal cancer.
Eligibility:
- Individuals at least 18 years of age who have solid tumors or colorectal cancer that has
not responded to other treatments.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will also be collected. Tumor tissue samples may be collected as well before
and after treatment. Imaging studies will also be performed.
- Participants will take ISIS 183750 once a week for 28-day cycles of treatment. On the
first cycle, they will also have ISIS 183750 on days 3 and 5.
- Participants will take irinotecan every second week, beginning on day 15 of the first
cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Treatment will continue as long as the cancer does not grow and the side effects are
not severe.
Background:
The eukaryotic translation initiation factor - eIF4E - is a potent oncogene that is found to
be dysregulated in approximately 30% of human cancers. Upregulation of eIF4E is an early
event in colorectal cancer (CRC) and correlates with CRC progression. ISIS 183750 is a
second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the
human eukaryotic translation initiation factor 4E (eIF4E) protein.
Objectives:
Primary:
To establish Maximum Tolerated Dose (MTD) and establish safety for the combination of ISIS
183750 and irinotecan in advanced solid tumors.
Secondary:
- To evaluate Response Rate, PFS, OS for the combination of ISIS 183750 and irinotecan in
advanced irinotecan-refractory colorectal cancer.
- To perform correlative studies to evaluate the effect of eIF4E inhibition on relevant
regulated proteins and immune cells.
- To characterize the plasma pharmacokinetic (PK) parameters for ISIS 183750 in the
absence and presence of irinotecan
- To characterize the plasma PK parameters for irinotecan in the presence of ISIS 183750
Eligibility:
-Adult patients with irinotecan-resistant colorectal cancer.
Design:
- This is a single-arm phase I/II study whereby all patients will receive the combination
of ISIS 183750 and irinotecan. All cycles are 28 days.
- Cycle 1 only: ISIS 183750 will be administered intravenously on Cycle 1 Days 1, 3, 5,
8, 15 and 22.
- Cycle 2 and beyond: ISIS 183750 will be administered as an intravenous infusion every
week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be
re-staged every 8 weeks.
- Irinotecan will be administered at a dose of 160mg/m2 as an intravenous infusion every
second week commencing on Day 15 of Cycle 1. The primary endpoint of the study will be
to establish MTD for the combination of ISIS 183750 and irinotecan in advanced solid
tumors. The phase II portion of the study will be confined to irinotecan-refractory
colorectoal cancer. Irinotecan-refractory will be defined as patients who have
radiological evidence of disease progression whilst receiving irinotecan or within 3
months after completing it.
- Correlative studies will comprise: Mandatory pre- and post- dose biopsies for eIF4e
mRNA and protein (IHC) analysis will be performed in the phase II portion of the study;
Immune subsets; PET responses (only in expansion cohort); Pharmacokinetic data
regarding the interaction of irinotecan and ISIS183750 in 10-12 patients.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |